Cusabio) CD47, an important 'escape door' for tumor cells
작성자
abbabio
작성일자
2020-11-23
조회수
366
If you are unable to see the message below, click here to view
On September 4th, 2020, IMAB and AbbVie jointly announced the establishment of a broad global partnership of the innovative CD47 monoclonal antibody lemzoprlimab (TJC4) independently developed by IMAB. So far, innovative tumor immunotherapy once again grabbed the attention of publics, but this time it wasn’t PD-L1, but CD47.
CD47, an integrin-related protein, participates in a series of physiological processes (including cell proliferation, apoptosis, migration, phagocytosis, and innate immune response) by interacting with its corresponding receptors (TSP1 and SIRPα). And CD47- SIRPαis a key process to stimulate cell fusion and T cell activation, especially to inhibit macrophages from phagocytosis of target cells.
In order to keep up with research hotspot, CUSABIO has developed a CD47 protein (CSB-MP004940HU) expressed in mammalian cell with high purity and low endotoxin. This protein has undergone multiple activity validation, including functional ELISA and LSPR assay.
Details Display
Functional ELISA
Measured by its binding ability in a functional ELISA. Immobilized SIRPA (CSB-MP021334HU) at 2 μg/ml can bind human CD47, the EC50 of human CD47 protein is 65.91-82.42 ng/ml.
Purity
Greater than 93% as determined by SDS-PAGE ((Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel).
LSPR Assay
Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.
